| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Pulmonary and Critical Care Division (Dr. Celli), St. Elizabeth’s Medical Center, Boston. MA; Division of Pulmonary Medicine (Dr. ZuWallack), St. Francis Hospital and Medical Center, Hartford, CT; and Boehringer Ingelheim (Drs. Wang and Kesten), Ridgefield, CT.
Correspondence to: Bartolome Celli, MD, FCCP, St. Elizabeth’s Medical Center, 36 Cambridge St, Boston, MA 02135; e-mail: bcelli{at}cchcs.org
Background: In patients with COPD, changes in inspiratory capacity (IC) have shown a higher correlation to patient-focused outcomes, such as dyspnea with exercise, than other standard spirometric measurements. Changes in IC reflect changes in hyperinflation. Tiotropium is a once-daily inhaled anticholinergic that has its effect through prolonged M3 muscarinic receptor antagonism and has demonstrated sustained improvements in spirometric and health outcomes. We sought to evaluate changes in resting IC and lung volumes after long-term administration of tiotropium.
Methods: To evaluate the effect of tiotropium, 18 µg/d, on IC, a 4-week, randomized, double-blind, placebo-controlled study was conducted in 81 patients with stable COPD. At each of the visits (weeks 0, 2, and 4) FEV1, FVC, IC, slow vital capacity (SVC), and thoracic gas volume (TGV) were measured prior to study drug (- 60 and - 15 min) and after study drug (30 min, 60 min, 120 min, and 180 min).
Results: Mean age was 64 years; 62% were men. Mean baseline FEV1 was 1.12 L (43% predicted). The mean differences (tiotropium - placebo) in FEV1 trough (morning before drug), peak, and area under the curve over 3 h values (adjusted for baseline and center differences) at week 4 were 0.16 L, 0.22 L, and 0.22 L, respectively (p < 0.01 for all); differences in IC for these variables were 0.22 L, 0.35 L, and 0.30 L (p < 0.01 for all). Differences in TGV were - 0.54 L, - 0.60 L, and - 0.70 L, respectively (p < 0.01 for all). The percentage improvement in area under the curve above baseline with tiotropium was similar among FEV1 and lung volumes (FEV1, 18%; FVC, 20%; SVC, 16%; IC, 16%; TGV, 14%).
Conclusions: Observed improvements in IC and reductions in TGV with once-daily tiotropium reflect improvements in hyperinflation that are maintained over 24 h.
Key Words: bronchodilator • COPD • inspiratory capacity • lung volumes • tiotropium
This article has been cited by other articles:
|
|
 |
|
  K. F. Rabe, W. Timmer, A. Sagkriotis, and K. Viel Comparison of a Combination of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Moderate COPD Chest, August 1, 2008; 134(2): 255 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Celli Update on the Management of COPD Chest, June 1, 2008; 133(6): 1451 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Gelb, C. F. Taylor, P. A. McClean, C. M. Shinar, M. T. Rodrigues, C. A. Gutierrez, K. R. Chapman, and N. Zamel Tiotropium and Simplified Detection of Dynamic Hyperinflation Chest, March 1, 2007; 131(3): 690 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. P. Albuquerque, L. E. Nery, D. S. Villaca, T. Y. S. Machado, C. C. Oliveira, A. T. Paes, and J. A. Neder Inspiratory fraction and exercise impairment in COPD patients GOLD stages II-III Eur. Respir. J., November 1, 2006; 28(5): 939 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R G Barr, J Bourbeau, C A Camargo, and F S F Ram Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis Thorax, October 1, 2006; 61(10): 854 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. O'Donnell, F. Sciurba, B. Celli, D. A. Mahler, K. A. Webb, C. J. Kalberg, and K. Knobil Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD. Chest, September 1, 2006; 130(3): 647 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Dusser, M-L. Bravo, P. Iacono, and on behalf the MISTRAL study group The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J., March 1, 2006; 27(3): 547 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. O'Donnell Is Sustained Pharmacologic Lung Volume Reduction Now Possible in COPD? Chest, March 1, 2006; 129(3): 501 - 503. [Full Text] [PDF]
|
|
|
|
|
|
J. A. van Noord, J. L. Aumann, E. Janssens, J. Verhaert, J. J. Smeets, A. Mueller, and P. J. G. Cornelissen Effects of Tiotropium With and Without Formoterol on Airflow Obstruction and Resting Hyperinflation in Patients With COPD Chest, March 1, 2006; 129(3): 509 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. Ferguson Why does the lung hyperinflate? Proceedings of the ATS, January 1, 2006; 3(2): 176 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. O'Donnell Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proceedings of the ATS, January 1, 2006; 3(2): 180 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Niewoehner, K. Rice, C. Cote, D. Paulson, J. A. D. Cooper Jr., L. Korducki, C. Cassino, and S. Kesten Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator: A Randomized Trial Ann Intern Med, September 6, 2005; 143(5): 317 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Turino Therapeutic Gains of Prolonged Bronchial Dilatation in Chronic Obstructive Pulmonary Disease Ann Intern Med, September 6, 2005; 143(5): 386 - 387. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Vincken Bronchodilator treatment of stable COPD: long-acting anticholinergics Eur. Respir. Rev., September 1, 2005; 14(94): 23 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Somand and T. L Remington Tiotropium: A Bronchodilator for Chronic Obstructive Pulmonary Disease Ann. Pharmacother., September 1, 2005; 39(9): 1467 - 1475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. A. Calverley Long-acting inhaled bronchodilators in COPD: how many drugs do we need? Eur. Respir. J., August 1, 2005; 26(2): 190 - 191. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barnes and R. A. Stockley COPD: current therapeutic interventions and future approaches Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C B Cooper and D P Tashkin Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease BMJ, March 19, 2005; 330(7492): 640 - 644. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Casanova, C. Cote, J. P. de Torres, A. Aguirre-Jaime, J. M. Marin, V. Pinto-Plata, and B. R. Celli Inspiratory-to-Total Lung Capacity Ratio Predicts Mortality in Patients with Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., March 15, 2005; 171(6): 591 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Casaburi, D. Kukafka, C. B. Cooper, T. J. Witek Jr, and S. Kesten Improvement in Exercise Tolerance With the Combination of Tiotropium and Pulmonary Rehabilitation in Patients With COPD Chest, March 1, 2005; 127(3): 809 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Gross Tiotropium Bromide Chest, December 1, 2004; 126(6): 1946 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.T. McNicholas, P.M.A. Calverley, A. Lee, and J.C. Edwards Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD Eur. Respir. J., June 1, 2004; 23(6): 825 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.R. Celli, W. MacNee, A. Agusti, A. Anzueto, B. Berg, A.S. Buist, P.M.A. Calverley, N. Chavannes, T. Dillard, B. Fahy, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur. Respir. J., June 1, 2004; 23(6): 932 - 946. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
